688136 科兴制药
已收盘 07-23 15:00:02
资讯
新帖
简况
港股异动 | 山东新华制药股份(00719)涨超4% 与科兴制药就二十碳五烯酸乙酯软胶囊出海中东达成合作
智通财经 · 07-13
港股异动 | 山东新华制药股份(00719)涨超4% 与科兴制药就二十碳五烯酸乙酯软胶囊出海中东达成合作
每周股票复盘：科兴制药（688136）限制性股票归属72.775万股
证券之星 · 07-12
每周股票复盘：科兴制药（688136）限制性股票归属72.775万股
科兴制药涨6.09%，东吴证券二个月前给出“买入”评级
证券之星 · 07-10
科兴制药涨6.09%，东吴证券二个月前给出“买入”评级
科兴制药（688136）披露2024年限制性股票激励计划第二个归属期归属结果暨股份上市公告，7月7日股价下跌6.55%
证券之星 · 07-07
科兴制药（688136）披露2024年限制性股票激励计划第二个归属期归属结果暨股份上市公告，7月7日股价下跌6.55%
科兴制药（688136）披露关于向激励对象授予限制性股票的公告，7月2日股价下跌0.27%
证券之星 · 07-02
科兴制药（688136）披露关于向激励对象授予限制性股票的公告，7月2日股价下跌0.27%
科兴制药涨6.04%，东吴证券二个月前给出“买入”评级
证券之星 · 07-01
科兴制药涨6.04%，东吴证券二个月前给出“买入”评级
股市必读：科兴制药（688136）6月26日收盘跌12.58%，主力净流入430.63万元
证券之星 · 06-29
股市必读：科兴制药（688136）6月26日收盘跌12.58%，主力净流入430.63万元
每周股票复盘：科兴制药（688136）推494.30万股限制性股票激励计划
证券之星 · 06-28
每周股票复盘：科兴制药（688136）推494.30万股限制性股票激励计划
科兴制药（688136）披露2026年限制性股票激励计划激励对象名单公示情况说明及核查意见，6月26日股价下跌12.58%
证券之星 · 06-26
科兴制药（688136）披露2026年限制性股票激励计划激励对象名单公示情况说明及核查意见，6月26日股价下跌12.58%
科兴制药涨13.21%，东吴证券一个月前给出“买入”评级
证券之星 · 06-25
科兴制药涨13.21%，东吴证券一个月前给出“买入”评级
每周股票复盘：科兴制药（688136）募投项目延期至2027年8月
证券之星 · 06-20
每周股票复盘：科兴制药（688136）募投项目延期至2027年8月
科兴制药(688136.SH)拟推2026年限制性股票激励计划
智通财经网 · 06-15
科兴制药(688136.SH)拟推2026年限制性股票激励计划
科兴制药：GB19注射液I期临床试验完成首例参与者入组
证券之星 · 06-15
科兴制药：GB19注射液I期临床试验完成首例参与者入组
每周股票复盘：科兴制药（688136）GB24管线具全球首创潜力
证券之星 · 06-14
每周股票复盘：科兴制药（688136）GB24管线具全球首创潜力
科兴制药：深圳市前海铂悦投资管理有限公司、深圳前海同增资本管理有限公司等多家机构于6月4日调研我司
证券之星 · 06-08
科兴制药：深圳市前海铂悦投资管理有限公司、深圳前海同增资本管理有限公司等多家机构于6月4日调研我司
创新药进展 | 科兴制药眼科新药Gb10在华启动I期临床试验 首例受试者入组
美股速递 · 06-04
创新药进展 | 科兴制药眼科新药Gb10在华启动I期临床试验 首例受试者入组
股市必读：科兴制药（688136）今年截至6月2日累计跌幅已超30%
证券之星 · 06-03
股市必读：科兴制药（688136）今年截至6月2日累计跌幅已超30%
股市必读：科兴制药（688136）今年截至5月22日累计跌幅已超25%
证券之星 · 05-25
股市必读：科兴制药（688136）今年截至5月22日累计跌幅已超25%
每周股票复盘：科兴制药（688136）GB10注射液完成首例入组
证券之星 · 05-17
每周股票复盘：科兴制药（688136）GB10注射液完成首例入组
科兴制药(688136.SH)：GB10注射液I期临床试验完成首例受试者入组给药
智通财经 · 05-13
科兴制药(688136.SH)：GB10注射液I期临床试验完成首例受试者入组给药
加载更多
公司概况
公司名称：
科兴生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-12-14
主营业务：
科兴生物制药股份有限公司的主营业务是重组蛋白、抗体及靶向递送疗法的研发、生产与商业化。公司的主要产品是人促红素注射液、注射用人干扰素α1b、人粒细胞刺激因子注射液、酪酸梭菌二联活菌散/胶囊。截止2025年12月31日，公司在国内已拥有专利72项，其中发明专利48项，外观专利21项，实用新型专利3项。
发行价格：
22.33
{"stockData":{"symbol":"688136","market":"SH","secType":"STK","nameCN":"科兴制药","latestPrice":18.56,"timestamp":1784790002000,"preClose":18.72,"halted":0,"volume":4838286,"delay":0,"changeRate":-0.0085,"floatShares":202000000,"shares":202000000,"eps":0.5548,"marketStatus":"已收盘","change":-0.16,"latestTime":"07-23 15:00:02","open":18.73,"high":18.78,"low":18.1,"amount":89235500,"amplitude":0.0363,"askPrice":18.56,"askSize":12,"bidPrice":18.55,"bidSize":220,"shortable":0,"etf":0,"ttmEps":0.5548,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":5,"adr":0,"adjPreClose":18.72,"symbolType":"stock_kcb","openAndCloseTimeList":[[1784770200000,1784777400000],[1784782800000,1784790000000]],"highLimit":20.59,"lowLimit":16.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201985000,"isCdr":false,"pbRate":2.17,"roa":"--","peRate":33.453497,"roe":"--","epsLYR":0.79,"committee":0.311688,"marketValue":3749000000,"turnoverRate":0.024,"status":1,"afterMarket":{"amount":0,"volume":0,"close":18.56,"buyVolume":0,"sellVolume":700,"time":1784792037746,"indexStatus":"已收盘 07-23 15:30:00","preClose":18.72},"floatMarketCap":3749000000},"requestUrl":"/m/hq/s/688136","defaultTab":"news","newsList":[{"id":"2651319523","title":"港股异动 | 山东新华制药股份(00719)涨超4% 与科兴制药就二十碳五烯酸乙酯软胶囊出海中东达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651319523","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651319523?lang=zh_cn&edition=full","pubTime":"2026-07-13 14:23","pubTimestamp":1783923780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，山东新华制药股份(00719)涨超4%，截至发稿，涨3.79%，报6.02港元，成交额999.02万港元。消息面上，据科兴制药官微消息，近日，科兴制药与山东新华制药股份有限公司(简称“新华制药”)再度携手，就二十碳五烯酸乙酯软胶囊出海沙特阿拉伯和阿联酋达成合作。这是双方继碳酸司维拉姆片之后的又一重要合作，共同推动国产高纯度EPA制剂进入中东两大核心医药市场。新华制药二十碳五烯酸乙酯软胶囊于2025年6月获得国家药品监督管理局颁发的《药品注册证书》，实现国产EPA制剂从原料到制剂的全链条自主可控。目前，该药品已向美国食品药品监督管理局(FDA)递交注册申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719","BK1515","BK1191","KCAI","BK0239","VXUS","BK4588","688136","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154650","title":"每周股票复盘：科兴制药（688136）限制性股票归属72.775万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650154650?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:21","pubTimestamp":1783794070,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，科兴制药报收于21.43元，较上周的22.08元下跌2.94%。本周关注点公司公告汇总：2024年限制性股票激励计划第二期归属727,750股，上市日期为2026年7月13日。公司公告汇总关于2024年限制性股票激励计划第二个归属期归属结果暨股份上市的公告科兴生物制药股份有限公司完成2024年限制性股票激励计划第二个归属期的股份登记，本次归属股票数量为727,750股，来源为公司向激励对象定向发行A股普通股，上市流通日期为2026年7月13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183596","title":"科兴制药涨6.09%，东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650183596?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:19","pubTimestamp":1783671560,"startTime":"0","endTime":"0","summary":"今日科兴制药（688136）涨6.09%，收盘报21.43元。2026年4月29日，东吴证券研究员朱国广,刘若彤发布了对科兴制药的研报《2025年报&2026年一季报点评：创新药潜力较大，出海业务维持较高增速》，该研报对科兴制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为64.49%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为平安证券的曹艳凯。科兴制药（688136）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000028666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649393531","title":"科兴制药（688136）披露2024年限制性股票激励计划第二个归属期归属结果暨股份上市公告，7月7日股价下跌6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649393531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649393531?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:20","pubTimestamp":1783434018,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，科兴制药报收于20.97元，较前一交易日下跌6.55%，最新总市值为42.2亿元。近日，科兴生物制药股份有限公司发布《关于2024年限制性股票激励计划第二个归属期归属结果暨股份上市的公告》。公告显示，公司已完成2024年限制性股票激励计划第二个归属期的股份登记工作，本次归属股票数量为727,750股，来源为公司向激励对象定向发行A股普通股，上市流通日期为2026年7月13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700041599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685061","title":"科兴制药（688136）披露关于向激励对象授予限制性股票的公告，7月2日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648685061?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:35","pubTimestamp":1783002916,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，科兴制药报收于21.9元，较前一交易日下跌0.27%，最新总市值为44.08亿元。近日，科兴生物制药股份有限公司发布《关于向激励对象授予限制性股票的公告》。公告显示，公司于2026年7月2日召开董事会，确定向197名激励对象授予494.3万股限制性股票，授予价格为14.35元/股，股票来源为二级市场回购或定向发行。本次授予的限制性股票为第二类，归属期分别为授予日起12个月和24个月后，每次归属50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515726","title":"科兴制药涨6.04%，东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648515726?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:38","pubTimestamp":1782895123,"startTime":"0","endTime":"0","summary":"今日科兴制药（688136）涨6.04%，收盘报21.96元。2026年4月29日，东吴证券研究员朱国广,刘若彤发布了对科兴制药的研报《2025年报&2026年一季报点评：创新药潜力较大，出海业务维持较高增速》，该研报对科兴制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为64.49%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为平安证券的曹艳凯。科兴制药（688136）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647345593","title":"股市必读：科兴制药（688136）6月26日收盘跌12.58%，主力净流入430.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647345593","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647345593?lang=zh_cn&edition=full","pubTime":"2026-06-29 04:20","pubTimestamp":1782678022,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，科兴制药报收于18.06元，下跌12.58%，换手率7.3%，成交量14.7万手，成交额2.77亿元。交易信息汇总股价提醒6月26日科兴制药收盘报18.06元，跌12.58%，当日成交2.77亿元。前10个交易日主力资金累计净流入77.87万元，股价累计下跌12.58%；融资余额累计减少373.52万元，融券余量累计减少9股。公司于2026年6月16日至6月25日在内部公示激励对象名单，公示期间未收到任何异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900001348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315545","title":"每周股票复盘：科兴制药（688136）推494.30万股限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315545","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646315545?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:17","pubTimestamp":1782587830,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，科兴制药报收于18.06元，较上周的18.29元下跌1.26%。本周，科兴制药6月25日盘中最高价报21.7元。本周关注点来自公司公告汇总：科兴制药拟授予494.30万股限制性股票实施股权激励。公司公告汇总董事会薪酬与考核委员会对《2026年限制性股票激励计划（草案）》的激励对象名单进行了公示与核查。本次激励计划拟授予494.30万股限制性股票，旨在建立长效激励机制，吸引和留住优秀人才，调动员工积极性，推动公司长期发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365747","title":"科兴制药（688136）披露2026年限制性股票激励计划激励对象名单公示情况说明及核查意见，6月26日股价下跌12.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365747","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646365747?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:45","pubTimestamp":1782485120,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，科兴制药报收于18.06元，较前一交易日下跌12.58%，最新总市值为36.35亿元。该股当日开盘20.59元，最高20.96元，最低17.73元，成交额达2.77亿元，换手率为7.3%。近日，科兴生物制药股份有限公司披露《董事会薪酬与考核委员会关于公司2026年限制性股票激励计划激励对象名单的公示情况说明及核查意见》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646736658","title":"科兴制药涨13.21%，东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2646736658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646736658?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:35","pubTimestamp":1782376519,"startTime":"0","endTime":"0","summary":"今日科兴制药（688136）涨13.21%，收盘报20.66元。2026年4月29日，东吴证券研究员朱国广,刘若彤发布了对科兴制药的研报《2025年报&2026年一季报点评：创新药潜力较大，出海业务维持较高增速》，该研报对科兴制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为64.49%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为平安证券的曹艳凯。科兴制药（688136）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500029576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644814065","title":"每周股票复盘：科兴制药（688136）募投项目延期至2027年8月","url":"https://stock-news.laohu8.com/highlight/detail?id=2644814065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644814065?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:41","pubTimestamp":1781894469,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，科兴制药报收于18.29元，较上周的19.08元下跌4.14%。本周关注点来自公司公告汇总：药物生产基地改扩建项目延期至2027年8月31日。2026年限制性股票激励计划激励对象名单科兴生物制药股份有限公司公布2026年限制性股票激励计划激励对象名单，共计197人获授494.30万股限制性股票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643635206","title":"科兴制药(688136.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2643635206","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643635206?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:00","pubTimestamp":1781524811,"startTime":"0","endTime":"0","summary":"科兴制药(688136.SH)披露2026年限制性股票激励计划(草案)，激励计划拟授予激励对象的限制性股票数量为494.3万股，占激励计划草案公告日公司股本总额的2.46%。限制性股票的授予价格为每股14.35元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/4.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/4.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643087812","title":"科兴制药：GB19注射液I期临床试验完成首例参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2643087812","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643087812?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:49","pubTimestamp":1781524166,"startTime":"0","endTime":"0","summary":"科兴制药(688136.SH)公告称，公司全资子公司深圳科兴自主研发的靶向BDCA2创新药物GB19注射液I期临床研究成功完成首例参与者入组给药。该药物有望为皮肤型红斑狼疮、系统性红斑狼疮等自身免疫性疾病患者提供新的治疗选择。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500029606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643721720","title":"每周股票复盘：科兴制药（688136）GB24管线具全球首创潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2643721720","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643721720?lang=zh_cn&edition=full","pubTime":"2026-06-14 01:45","pubTimestamp":1781372716,"startTime":"0","endTime":"0","summary":"截至2026年6月12日收盘，科兴制药报收于19.08元，较上周的19.65元下跌2.9%。本周，科兴制药6月9日盘中最高价报19.76元。本周关注点来自机构调研要点：GB24是全球首创TL1/LIGHT双特异性抗体，具“抗炎+抗纤维化”双效机制。临床前动物模型数据已证实，GB24在抑制溃疡和纤维化方面效果显著，能够切实改善肠道功能和细微结构，推动IBD进入全病程管理的新阶段。GB24凭借其极具差异化的双靶点设计和明确的临床未满足需求，在IBD赛道中具备极强的稀缺性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400000407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641486284","title":"科兴制药：深圳市前海铂悦投资管理有限公司、深圳前海同增资本管理有限公司等多家机构于6月4日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2641486284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641486284?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:02","pubTimestamp":1780916520,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年6月8日科兴制药发布公告称深圳市前海铂悦投资管理有限公司、深圳前海同增资本管理有限公司、深圳市瑞兆资产管理有限公司、深圳市金田私募证券基金管理有限公司、深圳红岸私募证券基金管理有限公司、深圳市普宏投资有限公司中邦基金、涵崧资产管理(珠海)有限责任公司、懂私慕、投资者于2026年6月4日调研我司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800028491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196752963","title":"创新药进展 | 科兴制药眼科新药Gb10在华启动I期临床试验 首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1196752963","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196752963?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:55","pubTimestamp":1780570522,"startTime":"0","endTime":"0","summary":"创新药研发领域迎来新动态。科兴制药旗下用于眼科治疗的在研创新药Gb10，已在中国正式启动I期临床试验。近日，该试验的首例受试者成功完成入组，标志着该药物的临床开发进程迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640947246","title":"股市必读：科兴制药（688136）今年截至6月2日累计跌幅已超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640947246","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640947246?lang=zh_cn&edition=full","pubTime":"2026-06-03 01:46","pubTimestamp":1780422376,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，科兴制药报收于20.18元，下跌4.41%，换手率1.89%，成交量3.8万手，成交额7672.25万元。当日关注点来自交易信息汇总：科兴制药6月2日收盘价20.18元，跌4.41%，年内累计跌幅达30.61%。前10个交易日资金流向情况：主力资金累计净流出7298.92万元，股价累计下跌10.53%；融资余额累计减少941.71万元，融券余量累计减少516股。该股最近90天内共有4家机构给出评级，买入评级1家，增持评级3家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300001950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638301084","title":"股市必读：科兴制药（688136）今年截至5月22日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638301084","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638301084?lang=zh_cn&edition=full","pubTime":"2026-05-25 01:29","pubTimestamp":1779643750,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，科兴制药报收于22.86元，下跌4.71%，换手率2.59%，成交量5.21万手，成交额1.21亿元。交易信息汇总股价提醒5月22日科兴制药收盘报22.86元，跌4.71%，当日成交521.16万元。该股已连续3日下跌，当年累计跌幅27.42%。资金流向5月22日主力资金净流出2381.67万元，占总成交额19.75%；游资资金净流入1502.11万元，占总成交额12.46%；散户资金净流入879.56万元，占总成交额7.3%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500000628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636647860","title":"每周股票复盘：科兴制药（688136）GB10注射液完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2636647860","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636647860?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:46","pubTimestamp":1778960772,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，科兴制药报收于24.72元，较上周的25.05元下跌1.32%。本周，科兴制药5月11日盘中最高价报27.36元。科兴生物制药股份有限公司于2026年5月12日召开2025年年度股东会，会议由董事长邓学勤主持，采用现场与网络投票方式举行。出席股东所持表决权占公司总表决权的51.9169%，所有议案均获通过。公司全资子公司深圳科兴药业有限公司自主研发的GB10注射液I期临床试验已完成首例受试者入组给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635378121","title":"科兴制药(688136.SH)：GB10注射液I期临床试验完成首例受试者入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2635378121","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635378121?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:53","pubTimestamp":1778673217,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科兴制药(688136.SH)公告，近日，公司全资子公司深圳科兴药业有限公司(“深圳科兴”)自主研发的眼科制剂“GB10注射液”I期临床研究成功完成首例受试者入组给药。据悉，深圳科兴GB10注射液正在开展一项旨在评价GB10在新生血管性年龄相关性黄斑变性(nAMD)患者的安全性、耐受性、药代动力学和有效性的Ⅰ期临床研究，并于近日成功完成首例受试者入组给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784829610449,"stockEarnings":[{"period":"1week","weight":-0.1475},{"period":"1month","weight":-0.0101},{"period":"3month","weight":-0.3442},{"period":"6month","weight":-0.4506},{"period":"1year","weight":-0.6268},{"period":"ytd","weight":-0.4063}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0498},{"period":"6month","weight":-0.0627},{"period":"1year","weight":0.0822},{"period":"ytd","weight":-0.0232}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"科兴生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13578人(较上一季度增加23.82%)","perCapita":"14875股","listingDate":"2020-12-14","address":"山东省济南市章丘区埠村街道创业路2666号","registeredCapital":"20198万元","survey":" 科兴生物制药股份有限公司的主营业务是重组蛋白、抗体及靶向递送疗法的研发、生产与商业化。公司的主要产品是人促红素注射液、注射用人干扰素α1b、人粒细胞刺激因子注射液、酪酸梭菌二联活菌散/胶囊。截止2025年12月31日，公司在国内已拥有专利72项，其中发明专利48项，外观专利21项，实用新型专利3项。","listedPrice":22.33},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科兴制药(688136)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科兴制药(688136)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科兴制药,688136,科兴制药股票,科兴制药股票老虎,科兴制药股票老虎国际,科兴制药行情,科兴制药股票行情,科兴制药股价,科兴制药股市,科兴制药股票价格,科兴制药股票交易,科兴制药股票购买,科兴制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科兴制药(688136)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科兴制药(688136)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}